Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MERREM I.V. as a 3 hour infusion every 8 hours · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MERREM I.V. 2g as a 3 hour infusion every 8 hours | DRUG | - |
| vancomycin I.V. 1 g every 12 hours | DRUG | - |
| tobramycin I.V. 5 mg/kg every 24 hours | DRUG | - |
| MERREM I.V. 1g as a 30 minute infusion every 8 hours | DRUG | - |
| MERREM I.V. 500 mg as a 3 hour infusion every 8 hours | DRUG | - |
Inclusion Criteria: * Onset or exacerbation of pneumonia at least 72 hours after admission to an acute care facility or onset of pneumonia in a nursing home or rehabilitation facility with subsequent transfer to an acute care facility * Diagnosis of hospital-acquired pneumonia requiring mechanical ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | - | Undisclosed |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | - | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | N/A | Undisclosed |
MERREM I.V. is used for the treatment of pneumonia, specifically ventilator-associated pneumonia and hospital-acquired pneumonia requiring mechanical ventilatory support. It is being studied as a 3 hour infusion administered every 8 hours. The drug is currently in Phase 3 clinical development for this infectious disease indication.
MERREM I.V. is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this small molecule drug for the treatment of pneumonia. Pfizer is responsible for the ongoing development and potential commercialization of this investigational therapy.
MERREM I.V. is in Phase 3 clinical development. A Phase 3 clinical trial has been completed for this drug, which was designed to evaluate its efficacy and safety in patients with pneumonia. The drug remains investigational and has not yet been approved by regulatory authorities for commercial use.
MERREM I.V. has been studied in one completed Phase 3 clinical trial with the identifier NCT00050401. This trial enrolled 500 participants in the United States and evaluated the drug in patients with ventilator-associated pneumonia or hospital-acquired pneumonia requiring mechanical ventilatory support. The trial included adults aged 18 years and older.
MERREM I.V. is administered as a 3 hour infusion every 8 hours. This dosing regimen was evaluated in the Phase 3 clinical trial for pneumonia. The drug is given intravenously, and the infusion duration and frequency are designed to maintain therapeutic levels in the body for the treatment of the infection.